MedWatch

Orphazyme's hour of reckoning approaches: "Its existence is threatened if it gets a clear no"

The US FDA will present its verdict on Orphazyme's drug candidate arimoclomol for treating NPC on June 17 at latest. According to an analyst and a former investor, the outcome is crucial to the Danish biotech firm.

Photo: Orphazyme/PR

Orphazyme's fate as a biotech company may be at stake when the US Food and Drug Administration (FDA) decides whether arimoclomol can be approved as a treatment for the rare metabolic disorder Niemann-Pick type C (NPC), says Danske Market's Senior Analyst Thomas Bowers.

"Clearly, its existence will be threatened if it gets a clear no and arimoclomol never gets to be an NPC product in the US," the analyst tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs